Baker Bros. Advisors’s Aquestive Therapeutics AQST Stock Holding History

Baker Bros. Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-99,600	Closed	-$317K	–	100
2019 Q3	$317K	Hold	99,600	–	–	﹤0.01%	106
2019 Q2	$418K	Hold	99,600	–	–	﹤0.01%	99
2019 Q1	$688K	Hold	99,600	–	–	﹤0.01%	92
2018 Q4	$627K	Hold	99,600	–	–	0.01%	88
2018 Q3	$1.74M	Buy	+99,600	New	+$1.64M	0.01%	86

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Baker Bros. Advisors's AQST Position: Q4 2019 in Review

Baker Bros. Advisors sold out of Aquestive Therapeutics (AQST) in Q4 2019, closing a stake of 99,600 shares — an estimated $317K sold.

Baker Bros. Advisors first reported a position in AQST in Q3 2018 and held it in 5 quarters. The position peaked at $1.74M in Q3 2018. 56 funds tracked by Wall St. Rank hold AQST as of Q4 2019.

Baker Bros. Advisors reported no remaining Aquestive Therapeutics position as of Q4 2019 after selling out during the quarter.
Baker Bros. Advisors sold 99,600 Aquestive Therapeutics shares in Q4 2019, an estimated $317K.
Baker Bros. Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and held it in 5 quarters.
Baker Bros. Advisors's Aquestive Therapeutics position peaked at $1.74M in Q3 2018.
56 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2019.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.